Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Amivantamab is a targeted therapy for specific non-small cell lung cancers, acting on EGFR and MET receptors.
• Cutaneous adverse events are common with amivantamab due to its mechanism of action.
• The case highlights a rare but severe dermatological complication associated with this treatment.

Purpose of the Study:

• To report a case of severe erosive pustular dermatosis (EPD) in a patient treated with amivantamab.
• To emphasize the importance of recognizing and managing this adverse event.
• To inform clinicians about a rare but significant side effect of amivantamab therapy.

Main Methods:

• A case presentation of a 67-year-old woman with metastatic adenosquamous carcinoma.
• Treatment with amivantamab following failure of first-line chemotherapy.
• Documentation of the development and management of severe erosive pustular dermatosis despite prophylactic measures.

Main Results:

• The patient developed severe erosive pustular dermatosis affecting over 50% of her scalp.
• The condition necessitated hair cutting for adequate local care.
• The patient required a treatment regimen including oral steroids, tetracyclines, and antibiotic creams.

Conclusions:

• Erosive pustular dermatosis is an exceptional and severe adverse event associated with amivantamab.
• Prompt recognition and intervention with systemic steroids, tetracyclines, and topical antibiotics are essential.
• Awareness among clinicians is critical to prevent severe consequences and recurrence.